SCHEMBL91626

SCHEMBL91626

C/C=N\C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427297 1.00
SCHEMBL366648 1.00
Water SCHEMBL28240728 0.94
Hydrochloric Acid SCHEMBL1775782 0.94
SCHEMBL684767 0.69
SCHEMBL11965827 0.62
SCHEMBL952545 0.62
SCHEMBL8280822 0.62
SCHEMBL10049422 0.62
SCHEMBL5416435 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2154266-B1 SURFACE TREATMENT LIQUID FOR ZINC-BASED METAL MATERIAL AND METHOD FOR SURFACE-TREATING ZINC-BASED METAL MATERIAL HENKEL AG & CO KGAA (DE) 2017-05-31 EP claimed
EP-3410468-B1 N-TYPE SEMICONDUCTOR ELEMENT, COMPLEMENTARY TYPE SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME, AND WIRELESS COMMUNICATION DEVICE IN WHICH THE SAME IS USED TORAY INDUSTRIES (JP) 2024-07-10 EP disclosed
WO-2024084056-A1 IONIZABLE LIPIDS ETHERNA IMMUNOTHERAPIES NV (BE) 2024-04-25 WO disclosed
US-11860156-B2 Bioanalytical analysis of site-specific antibody drug conjugates GENENTECH, INC. (US) 2024-01-02 US disclosed
US-20230337517-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-10-19 US disclosed
US-11730052-B2 Light-emitting device IDEMITSU KOSAN CO., LTD. (JP) 2023-08-15 US disclosed
US-11730052-B2 Light-emitting device IDEMITSU KOSAN CO., LTD. (JP) 2023-08-15 US disclosed
US-20230138288-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-05-04 US disclosed
US-20230130874-A1 Cysteine Engineered Antibodies and Conjugates GENENTECH, INC. (US) 2023-04-27 US disclosed
US-11616453-B2 Integrated circuit, method for manufacturing same, and radio communication device using same TORAY INDUSTRIES, INC. (JP) 2023-03-28 US disclosed
WO-2006052886-A1 METABOLITES OF CERTAIN [1,4]DIAZEPINO[6,7,1-IJ]QUINOLINE DERIVATIVES AND METHODS OF PREPARATION AND USE THEREOF WYETH (US) 2006-05-18 WO disclosed
US-20050053552-A1 Phase shift colloids as ultrasound contrast agents QUAY STEVEN C (US) 2005-03-10 US disclosed
US-20040116399-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2004-06-17 US disclosed
WO-2004014377-A1 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-6569404-B1 Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles AMERSHAM HEALTH A/S (NO) 2003-05-27 US disclosed
US-6245319-B1 Colloidal dispersions of perfluoropentane SONUS PHARMACEUTICALS, INC. 2001-06-12 US disclosed
EP-0680341-B1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMA INC (US) 2001-05-09 EP disclosed
EP-1038535-A2 Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents SONUS PHARMACEUTICALS, INC. (US) 2000-09-27 EP disclosed
EP-0680341-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1995-11-08 EP disclosed
WO-1994016739-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1994-08-04 WO disclosed